Authentic Holdings, Inc. — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that Authentic Holdings, Inc. filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Revenue
Total revenue from all business activities — the top line of the income statement. Represents all money earned before any expenses are deducted.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Dec 31, 2024 | $398.6K | Apr 16, 2025 |
| FY2024 | Dec 31, 2023 | $0 | Apr 16, 2025 |
| FY2023 | Dec 31, 2022 | $0 | Jun 12, 2024 |
| FY2022 | Dec 31, 2021 | $5.9K | Apr 21, 2023 |
| FY2021 | Dec 31, 2020 | $4.0K | Apr 15, 2022 |
| FY2020 | Dec 31, 2019 | $3.8K | Oct 12, 2021 |
| FY2019 | Dec 31, 2018 | $0 | Apr 21, 2021 |
| FY2017 | Dec 31, 2016 | $18.8K | Apr 2, 2018 |
| FY2016 | Dec 31, 2015 | $3.5K | Mar 31, 2017 |
| FY2014 | Dec 31, 2014 | $193.2K | Feb 27, 2017 |
Gross Profit
Revenue minus the cost of goods sold (COGS). Gross profit shows how much revenue remains to cover operating expenses, R&D, and administrative costs before calculating operating income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Dec 31, 2024 | $271.3K | Apr 16, 2025 |
| FY2024 | Dec 31, 2023 | $0 | Apr 16, 2025 |
| FY2023 | Dec 31, 2022 | $0 | Jun 12, 2024 |
| FY2022 | Dec 31, 2021 | ($58.0K) | Apr 21, 2023 |
| FY2021 | Dec 31, 2020 | ($22.9K) | Apr 15, 2022 |
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Dec 31, 2024 | ($1.32M) | Apr 16, 2025 |
| FY2024 | Dec 31, 2023 | ($1.66M) | Apr 16, 2025 |
| FY2023 | Dec 31, 2022 | ($1.16M) | Jun 12, 2024 |
| FY2022 | Dec 31, 2021 | ($1.40M) | Apr 21, 2023 |
| FY2021 | Dec 31, 2020 | ($1.14M) | Apr 15, 2022 |
| FY2020 | Dec 31, 2019 | ($1.66M) | Oct 12, 2021 |
| FY2019 | Dec 31, 2018 | ($445.3K) | Apr 21, 2021 |
| FY2018 | Dec 31, 2017 | ($847.2K) | Apr 16, 2019 |
| FY2017 | Dec 31, 2016 | ($819.0K) | Apr 2, 2018 |
| FY2016 | Dec 31, 2015 | ($19.13M) | Mar 31, 2017 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Dec 31, 2024 | ($725.9K) | Apr 16, 2025 |
| FY2024 | Dec 31, 2023 | ($660.9K) | Apr 16, 2025 |
| FY2023 | Dec 31, 2022 | ($415.0K) | Jun 12, 2024 |
| FY2022 | Dec 31, 2021 | ($341.4K) | Apr 21, 2023 |
| FY2021 | Dec 31, 2020 | ($366.2K) | Apr 15, 2022 |
| FY2020 | Dec 31, 2019 | ($664.0K) | Oct 12, 2021 |
| FY2019 | Dec 31, 2018 | ($334.7K) | Apr 21, 2021 |
| FY2018 | Dec 31, 2017 | ($795.1K) | Apr 16, 2019 |
| FY2017 | Dec 31, 2016 | ($1.26M) | Apr 2, 2018 |
| FY2016 | Dec 31, 2015 | ($16.51M) | Mar 31, 2017 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Dec 31, 2024 | $4.4K | Apr 16, 2025 |
| FY2024 | Dec 31, 2023 | $56.9K | Apr 16, 2025 |
| FY2023 | Dec 31, 2022 | $65.3K | Jun 12, 2024 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Dec 31, 2024 | ($126.7K) | Apr 16, 2025 |
| FY2024 | Dec 31, 2023 | ($227.2K) | Apr 16, 2025 |
| FY2023 | Dec 31, 2022 | ($998.7K) | Jun 12, 2024 |
| FY2022 | Dec 31, 2021 | ($174.3K) | Apr 21, 2023 |
| FY2021 | Dec 31, 2020 | ($12.1K) | Apr 15, 2022 |
| FY2020 | Dec 31, 2019 | ($586.0K) | Oct 12, 2021 |
| FY2019 | Dec 31, 2018 | ($3.2K) | Apr 21, 2021 |
| FY2018 | Dec 31, 2017 | ($122.9K) | Apr 16, 2019 |
| FY2017 | Dec 31, 2016 | ($232.3K) | Apr 2, 2018 |
| FY2016 | Dec 31, 2015 | ($465.9K) | Mar 31, 2017 |
Capital Expenditures (Capex)
Cash spent on acquiring or upgrading physical assets — property, equipment, and infrastructure. High capex businesses include manufacturing, telecom, and energy companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2023 | Dec 31, 2023 | $0 | Jun 12, 2024 |
| FY2023 | Dec 31, 2022 | $4.0K | Jun 12, 2024 |
| FY2022 | Dec 31, 2021 | $0 | Apr 21, 2023 |
| FY2020 | Dec 31, 2019 | $21.5K | Oct 12, 2021 |
| FY2019 | Dec 31, 2018 | $0 | Apr 21, 2021 |
| FY2016 | Dec 31, 2015 | $2.7K | Mar 31, 2017 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Dec 31, 2024 | $4.49M | Apr 16, 2025 |
| FY2024 | Dec 31, 2023 | $5.42M | Apr 16, 2025 |
| FY2023 | Dec 31, 2022 | $711.7K | Jun 12, 2024 |
| FY2022 | Dec 31, 2021 | $173.9K | Apr 21, 2023 |
| FY2021 | Dec 31, 2020 | $361.9K | Apr 15, 2022 |
| FY2020 | Dec 31, 2019 | $491.1K | Oct 12, 2021 |
| FY2019 | Dec 31, 2018 | $51.7K | Apr 21, 2021 |
| FY2018 | Dec 31, 2017 | $42.4K | Apr 16, 2019 |
| FY2017 | Dec 31, 2016 | $59.7K | Apr 2, 2018 |
| FY2016 | Dec 31, 2015 | $45.2K | Mar 31, 2017 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Dec 31, 2024 | $5.53M | Apr 16, 2025 |
| FY2024 | Dec 31, 2023 | $5.62M | Apr 16, 2025 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Dec 31, 2024 | ($1.04M) | Apr 16, 2025 |
| FY2024 | Dec 31, 2023 | ($205.5K) | Apr 16, 2025 |
| FY2024 | Dec 31, 2022 | ($4.52M) | Apr 16, 2025 |
| FY2023 | Dec 31, 2021 | ($3.68M) | Jun 12, 2024 |
| FY2022 | Dec 31, 2020 | ($2.78M) | Apr 21, 2023 |
| FY2021 | Dec 31, 2019 | ($2.87M) | Apr 15, 2022 |
| FY2020 | Dec 31, 2018 | ($1.67M) | Oct 12, 2021 |
| FY2019 | Dec 31, 2017 | ($1.38M) | Apr 21, 2021 |
| FY2018 | Dec 31, 2016 | ($1.31M) | Apr 16, 2019 |
| FY2017 | Dec 31, 2015 | ($1.26M) | Apr 2, 2018 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Dec 31, 2024 | ($39.36M) | Apr 16, 2025 |
| FY2024 | Dec 31, 2023 | ($38.04M) | Apr 16, 2025 |
| FY2023 | Dec 31, 2022 | ($36.38M) | Jun 12, 2024 |
| FY2022 | Dec 31, 2021 | ($35.22M) | Apr 21, 2023 |
| FY2021 | Dec 31, 2020 | ($33.82M) | Apr 15, 2022 |
| FY2020 | Dec 31, 2019 | ($32.69M) | Oct 12, 2021 |
| FY2019 | Dec 31, 2018 | ($31.02M) | Apr 21, 2021 |
| FY2018 | Dec 31, 2017 | ($30.58M) | Apr 16, 2019 |
| FY2017 | Dec 31, 2016 | ($29.73M) | Apr 2, 2018 |
| FY2016 | Dec 31, 2015 | ($28.91M) | Mar 31, 2017 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2023 | Dec 31, 2023 | $0 | Jun 12, 2024 |
| FY2023 | Dec 31, 2022 | $0 | Jun 12, 2024 |
| FY2022 | Dec 31, 2021 | $0 | Apr 21, 2023 |
| FY2021 | Dec 31, 2020 | $8.5K | Apr 15, 2022 |
| FY2021 | Dec 31, 2019 | $4.8K | Apr 15, 2022 |
| FY2020 | Dec 31, 2018 | $29.3K | Oct 12, 2021 |
| FY2019 | Dec 31, 2017 | $0 | Apr 21, 2021 |
| FY2018 | Dec 31, 2016 | $36.2K | Apr 16, 2019 |
| FY2017 | Dec 31, 2015 | $33.0K | Apr 2, 2018 |
| FY2016 | Dec 31, 2014 | $755 | Mar 31, 2017 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2021 | Dec 31, 2021 | 0 | Apr 15, 2022 |
| FY2021 | Dec 31, 2020 | 0 | Apr 15, 2022 |
| FY2020 | Dec 31, 2019 | 0 | Oct 12, 2021 |
| FY2019 | Dec 31, 2018 | 0 | Apr 21, 2021 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Dec 31, 2024 | 0 | Apr 16, 2025 |
| FY2024 | Dec 31, 2023 | 0 | Apr 16, 2025 |
Shares Outstanding
Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Dec 31, 2024 | 2.26B | Apr 16, 2025 |
| FY2024 | Dec 31, 2023 | 2.02B | Apr 16, 2025 |
| FY2023 | Dec 31, 2022 | 1.56B | Jun 12, 2024 |
| FY2022 | Dec 31, 2021 | 1.45B | Apr 21, 2023 |
| FY2021 | Dec 31, 2020 | 1.25B | Apr 15, 2022 |
| FY2020 | Dec 31, 2019 | 26.45M | Oct 12, 2021 |
| FY2019 | Dec 31, 2018 | 19.98M | Apr 21, 2021 |
| FY2018 | Dec 31, 2017 | 1.76M | Apr 16, 2019 |
| FY2017 | Dec 31, 2016 | 19.21M | Apr 2, 2018 |
| FY2016 | Dec 31, 2015 | 17.54M | Mar 31, 2017 |